Communiqués Bio-Thera Solutions, Ltd.

Actions

688177

CNE100003R98

Cours en clôture Shanghai S.E. Autres places de cotation 00:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
21,12 ^CNY	-1,08%		-6,26%	-48,79%

03/06	Bio-Thera Solutions reçoit un avis positif du CHMP pour Avzivi (Bevacizumab), un biosimilaire de l'Avastin	CI
02/06	Bio-Thera Solutions présente les données cliniques du BAT8006 (Folate Receptor-Alpha-ADC) au congrès annuel 2024 de l'American Society of Clinical Oncology (ASCO)	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK	29/05	AQ
Bio-Thera Solutions Receives IND Clearance from US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor	26/03	AQ
Recent Biosimilar Approvals	21/12	AQ
Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litigation in the U.S	25/10/23	AQ
Genentech Files BPCIA Complaint Against Biogen Regarding Tocilizumab	18/07/23	AQ
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, a Stelara® Biosimilar	16/06/23	BU
Bio-Thera Solutions Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting	17/04/23	AQ
Bio-Thera Solutions Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting	14/04/23	BU
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007, an Antibody-Drug Conjugate Targeting Nectin-4 for the Treatment of Advanced Solid Tumors	13/03/23	BU
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors	08/03/23	BU
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8010, an Antibody Drug Conjugate Targeting HER2 for the Treatment of Advanced Solid Tumors	06/03/23	BU
China NMPA Approves Bio-Thera Solutions' BAT1806, A Biosimilar to Actemra	17/01/23	AQ
China NMPA Approves Bio-Thera Solutions’ BAT1806, A Biosimilar to Actemra® (Tocilizumab)	16/01/23	BU
Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-?-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium	05/12/22	AQ
Bio-Thera Solutions Announces Presentation of BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Selection Summit	05/12/22	AQ
Bio-Thera Solutions Announces Presentation of BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Selection Summit	02/12/22	BU
Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-α-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium	02/12/22	BU
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306, a Proposed Biosimilar of Cosentyx® (Secukinumab)	01/11/22	BU
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab)	14/10/22	BU
Bio-Thera Solutions Announces Details of Poster Presentation of a Highly Thermal Stable Recombinant Bivalent Nanoparticle Vaccine Containing Spikes of SARS-CoV-2 Omicron and Delta at Vaccine Summit 2022	11/10/22	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Bio-Thera Solutions, Ltd.

Actions

688177

CNE100003R98

Communiqués

Filtres